The mission of the Bioinformatics Shared Resource (BISR) is to provide bioinformatic and biostatistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists engaged in the planning, conduct, analysis, and interpretation of research studies that use modern high-throughput technologies from molecular biology. Additionally, members of the BISR collaborate with oncology research scientists to develop bioinformatic and biostatistical methods to improve the efficiency of current and future basic science, therapeutic, diagnostic, prevention, and intervention studies. Members of the BISR have experience with mRNA expression microarrays from Affymetrix, Agilent, and Illumina, proteomics using mass spectrometry or two-dimensional polyacrylamide gel electrophoresis;serial analysis of gene expression;tissue microarrays;array comparative genomic hybridization;single nucleotide polymorphism chips;methylation arrays;microRNA arrays;exon tiling arrays;real-time polymerase chain reaction;and reverse-phase protein lysate arrays. The BISR provides advice on choosing technology platforms, experimental design, sample size and power computations, data preprocessing, statistical analysis, and bioinformatic interpretation. The services of the resource are directed toward three goals: (1) to ensure that all high-throughput experiments at M.D. Anderson are properly analyzed and interpreted, (2) to play a direct role in the planning and design of experiments that use these technologies, and (3) to provide educational programs in bioinformatics methods. During the previous funding period, the BISR assisted 244 investigators from 20 different programs. Use of the BISR doubled during the previous five years, and the number of publications by users of the BISR grew from 33 during the first year to 65 during the most recent year. In the future, we remain committed to providing support for the design and analysis of experiments using cutting-edge technologies and will work with M.D. Anderson researchers to understand the nature of the data generated from novel technologies. Where possible, we are standardizing our analyses and report generation by developing templates in Sweave, a tool that enhances the reproducibility of statistical analyses. We also plan to enhance our ability to offer sequence-based bioinformatics services such as ChlP-on-chip and motif finding. Finally, we are exploring innovative ways to integrate data, algorithms, and reports.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310862
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$166,099
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477
Liao, Zhongxing; Lee, J Jack; Komaki, Ritsuko et al. (2018) Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36:1813-1822
Ma, Junsheng; Hobbs, Brian P; Stingo, Francesco C (2018) Integrating genomic signatures for treatment selection with Bayesian predictive failure time models. Stat Methods Med Res 27:2093-2113

Showing the most recent 10 out of 12418 publications